# MSCI Genomic Healthcare Innov UCITS ETF (XGES)

**Page:** https://fundology.uk/fund/xges · ISIN IE000KD0BZ68

## At a glance

> Capital at risk. Past performance is not a guide to future returns. The value of investments can fall as well as rise.

As of 13/11/2026, XGES (MSCI Genomic Healthcare Innov UCITS ETF, ISIN IE000KD0BZ68) closed at £32.81 on the London Stock Exchange. Its ongoing charge is 0.36% a year (about £36 on £10,000). Over the three years to 13/11/2026 its price changed by +59.1%, or +43.7% after UK CPIH inflation.

## Summary

Xtrackers IE Plc - MSCI Genomic Healthcare Innov UCITS ETF is an exchange-traded fund (ETF) from Xtrackers, launched in 2022. It tracks the MSCI ACWI IMI Genomic Innovation Select ESG Screened 100 Index - Benchmark TR Net — large and medium-sized companies across developed and emerging markets. You buy and sell it through a share-dealing account or platform during stock-market hours, like a share. Its ongoing charge is 0.36% a year — about £36 a year on every £10,000 invested, taken from the fund's value rather than billed to you. Income from its investments is reinvested inside the fund, so it shows up as a rising price rather than cash paid to you.

Latest close: **£32.81** (13/11/2026).

## Key facts

| Fact | Value |
|---|---|
| Ticker (LSE) | XGES |
| ISIN | IE000KD0BZ68 |
| Also listed as | XGEN (London Stock Exchange, US dollars) |
| Category | Healthcare |
| Type | ETF |
| Provider | Xtrackers |
| Tracks | MSCI ACWI IMI Genomic Innovation Select ESG Screened 100 Index - Benchmark TR Net |
| Income | Accumulating |
| Ongoing charge | 0.36% a year (£36 per £10,000) |
| Fund size | £12.5m |
| Launched | 2022 |
| Domicile | Ireland |
| UK reporting fund status | Yes — on HMRC’s list of reporting funds (list of 02/11/2026); reporting fund since 12/07/2022 |

## Past returns (periods to 13/11/2026)

After the fund's ongoing charges. "Income reinvested" is total return; "price only" leaves out income paid out. Real returns are after UK CPIH inflation.

| Window | Return | After CPIH inflation | Measured as |
|---|---|---|---|
| 1 year | +30.06% | +25.45% | income reinvested |
| 3 years | +59.06% | +43.71% | price only |

Returns: as reported (delayed data) and worked out from recorded daily closes. Inflation: UK CPIH, latest month published.

## Calendar-year returns

Calendar-year returns of Xtrackers IE Plc - MSCI Genomic Healthcare Innov UCITS ETF in pounds (price, with income reinvested in the fund): 2023 −7.9%, 2024 +0.4%, 2025 +9.3%; 2026 to 13/11/2026 +27.1%. Returns of Xtrackers IE Plc - MSCI Genomic Healthcare Innov UCITS ETF in pounds (price, with income reinvested in the fund) over the 12 months to 30/09/2026: +41.0%; to 30/09/2025: +1.5%; to 30/09/2024: +5.3%; to 30/09/2023: −13.9%.

| Year | Return | After CPIH inflation | Measured as |
|---|---|---|---|
| 2023 | -7.9% | -11.6% | Price |
| 2024 | +0.4% | -3.0% | Price |
| 2025 | +9.3% | +5.6% | Price |
| 2026 to 13/11/2026 | +27.1% | +23.0% | Price |

## Risk metrics

| Window | Volatility | Max drawdown |
|---|---|---|
| 1 year | 23.70% | -12.65% |
| 3 years | 19.70% | -23.72% |

## Largest fall

Volatility of Xtrackers IE Plc - MSCI Genomic Healthcare Innov UCITS ETF in pounds, annualised from weekly returns to 13/11/2026: 23.7% over 1 year, 19.7% over 3 years. Largest fall in the price of Xtrackers IE Plc - MSCI Genomic Healthcare Innov UCITS ETF since July 2022, in pounds: −33.4% from 12/08/2022 to 11/04/2025. The lowest 12-month return of Xtrackers IE Plc - MSCI Genomic Healthcare Innov UCITS ETF in pounds (price, with income reinvested in the fund) since July 2022 was −23.6% (12 months to 10/11/2023); the highest was +43.2% (12 months to 21/08/2026). On 13/11/2026 the price of Xtrackers IE Plc - MSCI Genomic Healthcare Innov UCITS ETF was 2.5% below its highest weekly close since July 2022 (30/10/2026), in pounds.

## Charges compared with similar funds

Ongoing charge of Xtrackers IE Plc - MSCI Genomic Healthcare Innov UCITS ETF 0.36% a year. Compared on 14/11/2026, 10 of the 28 other healthcare funds charge more, 0 the same and 18 less (share classes counted once).

## Charges & eligibility

- Ongoing charges figure (OCF): **0.36%** per year (as of 13/11/2026)
- Stocks and shares ISA eligible: usually (check with your platform)
- SIPP eligible: usually (check with your provider)
- ISA and SIPP mean the kind of product usually qualifies under HMRC rules. We do not check each platform’s list — each provider decides which funds it offers. Crypto ETNs have not qualified for a stocks and shares ISA since 06/04/2026, and overseas funds that are not UK-recognised UCITS, such as Swiss ETFs, do not usually qualify.

## What it holds

As of 15/11/2026, XGES holds 104 positions, according to its published holdings. The largest is Moderna at 5.95% of the fund; the ten largest make up 46.7%.

### Top holdings

Largest positions (as of 15/11/2026), as a percentage of the whole fund:

| # | Holding | Ticker | Weight |
|---|---|---|---|
| 1 | Moderna | [MRNA](https://fundology.uk/stock/MRNA) | 5.95% |
| 2 | Agilent Technologies | [A](https://fundology.uk/stock/A) | 4.99% |
| 3 | Lonza Group | [LONN](https://fundology.uk/stock/LONN) | 4.95% |
| 4 | Danaher | [DHR](https://fundology.uk/stock/DHR) | 4.92% |
| 5 | Illumina | [ILMN](https://fundology.uk/stock/ILMN) | 4.58% |
| 6 | Roche | [RO](https://fundology.uk/stock/RO) | 4.57% |
| 7 | Natera | [NTRA](https://fundology.uk/stock/NTRA) | 4.45% |
| 8 | Vertex Pharmaceuticals | [VRTX](https://fundology.uk/stock/VRTX) | 4.40% |
| 9 | GSK American Depository Shares Rep | — | 4.29% |
| 10 | argenx | [ARGX](https://fundology.uk/stock/ARGX) | 3.61% |

## Where it invests

Shares of the whole fund. Bonds, cash and positions without a classification are shown as they come, not guessed.

### By country

Added up from the fund’s published holdings, as of 15/11/2026.

| Country | Weight |
|---|---|
| United States | 67.4% |
| Switzerland | 12.6% |
| China | 8.5% |
| Netherlands | 5.6% |
| United Kingdom | 4.5% |
| Spain | 0.4% |
| Sweden | 0.3% |
| Australia | 0.2% |
| Other countries | 0.4% |
| Not classified | 0.1% |

### By type of asset

Added up from the fund’s published holdings, as of 15/11/2026.

| Type of asset | Weight |
|---|---|
| Equity | 99.9% |
| Cash and money market | 0.1% |

The 100 holdings on record (of 104 reported): https://fundology.uk/fund/xges/holdings

## Questions people ask

**What is the ongoing charge of XGES?**

The ongoing charge of XGES is 0.36% a year — about £36 a year on every £10,000 invested, taken from the fund’s value rather than billed to you. Platform and dealing fees are charged separately. Ongoing charge of Xtrackers IE Plc - MSCI Genomic Healthcare Innov UCITS ETF 0.36% a year. Compared on 14/11/2026, 10 of the 28 other healthcare funds charge more, 0 the same and 18 less (share classes counted once).

**What does XGES track?**

XGES tracks the MSCI ACWI IMI Genomic Innovation Select ESG Screened 100 Index - Benchmark TR Net — large and medium-sized companies across developed and emerging markets.

**Is XGES accumulating or distributing?**

XGES is accumulating: income is reinvested inside the fund, so it shows up as a rising price rather than cash paid to you.

**What is the ISIN of XGES?**

The ISIN of XGES is IE000KD0BZ68. An ISIN identifies one exact share class of a fund; XGES is its ticker on the London Stock Exchange. The same share class is also listed as XGEN (London Stock Exchange, US dollars).

**What does XGES hold?**

As of 15/11/2026, XGES holds 104 positions, according to its published holdings. The largest is Moderna at 5.95% of the fund; the ten largest make up 46.7%. Its ten largest holdings are Moderna (5.95%), Agilent Technologies (4.99%), Lonza Group (4.95%), Danaher (4.92%), Illumina (4.58%), Roche (4.57%), Natera (4.45%), Vertex Pharmaceuticals (4.40%), GSK American Depository Shares Rep (4.29%) and argenx (3.61%).

**What were XGES’s returns in each of the last five years?**

Calendar-year returns of XGES in pounds (price, with income reinvested in the fund): 2023 −7.9%, 2024 +0.4%, 2025 +9.3%; 2026 to 13/11/2026 +27.1%. Past performance is not a guide to future returns.

**How has XGES done after inflation?**

Over the three years to 13/11/2026 XGES’s price changed by +59.1%, or +43.7% after UK CPIH inflation. Past performance is not a guide to future returns.

## Fund documents

- [Fund page at Xtrackers (DWS)](https://etf.dws.com/en-gb/IE000KD0BZ68-msci-genomic-healthcare-innovation-ucits-etf-1c/)
- Links checked 12/10/2026.

---

We show information. We are not financial advisers, not authorised by the FCA, and never recommend specific investments.

Capital at risk. Past performance is not a guide to future returns. The value of investments can fall as well as rise.